Treatment of nonalcoholic fatty liver disease: from adult trials to perspectives in the management of children and adolescents.

This editorial discusses how results from clinical trials in adult NAFLD patients can be translated to improved therapies of NAFLD in children and adolescents.
PUBLISHED IN: Expert Opin Pharmacother 2020

Commentary

NAFLD is considered the most predominant form of chronic liver disease in childhood/adolescence and its prevalence ranges from 7.6% to 34.2%. Since longitudinal studies of NAFLD/NASH in pediatric populations are mostly lacking, its management is extrapolated from adult studies. Beyond lifestyle modifications, the cornerstone of pediatric NAFLD treatment, numerous medications and supplements have been introduced for the management of pediatric NAFLD.

In clinical practice, diabetologists should consider NAFLD in patients with T2DM, a disease with high NAFLD prevalence and higher rates of NASH than the general population [7]. Patients with biopsy-proven NASH and/or significant fibrosis currently qualify for pharmacotherapy. Given the variety of pharmacological agents under investigation, the therapeutic future of NAFLD seems to be promising.

Share the article
Avatar photo

Dr. D. Beard

DR. D. BEARD is specialist of Nash Pathology

Articles: 191

Leave a Reply

Your email address will not be published. Required fields are marked *

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES